Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Immix Biopharma, Inc. - Common Stock
(NQ:
IMMX
)
3.070
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
94,564
Open
3.040
Bid (Size)
3.010 (3)
Ask (Size)
3.170 (2)
Prev. Close
3.070
Today's Range
3.000 - 3.230
52wk Range
1.400 - 7.750
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
March 20, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
March 05, 2024
Hear from the ~30,000 relapsed or refractory AL Amyloidosis patients in the United States today in their own words
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Performance
YTD
-49.34%
-49.34%
1 Month
-5.83%
-5.83%
3 Month
-54.25%
-54.25%
6 Month
-16.58%
-16.58%
1 Year
+72.47%
+72.47%
More News
Read More
BioMedNewsBreaks — Immix Biopharma Inc. (NASDAQ: IMMX) Closes on $15M Public Offering
February 09, 2024
Via
Investor Brand Network
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
February 08, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
February 07, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
February 05, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Announces Proposed Public Offering of Common Stock
February 05, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Why Humana Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
January 25, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
January 25, 2024
Via
Benzinga
Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products
January 24, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board
January 04, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board
December 18, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
December 15, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
December 14, 2023
Via
Benzinga
Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023
December 11, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit
November 30, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis
November 22, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing
November 21, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients
November 06, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients
November 06, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Subsidiary Nexcella Announces Dr. Michaela Liedtke, Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid Center, Joins Scientific Advisory Board
October 26, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
October 23, 2023
Via
Benzinga
Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site
October 16, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Inc. (NASDAQ: IMMX) Climbs to New 52-Week High
October 04, 2023
Via
Investor Brand Network
Immix Biopharma Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting
October 03, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.